Literature DB >> 2498260

Inhibition of colony formation of drug-resistant human tumor cell lines by combinations of interleukin-2-activated killer cells and antitumor drugs.

A Ohtsu1, Y Sasaki, T Tamura, Y Fujiwara, Y Ohe, K Minato, K Nakagawa, M Bungo, N Saijo.   

Abstract

The cytotoxicity of interleukin-2-activated killer (LAK) cells with or without anticancer drugs against cell lines with acquired drug resistance was evaluated in vitro by colony assay. Human non-small cell lung cancer cell lines, PC-9 and PC-14, human leukemia cell line, K-562, and their sublines resistant to cisplatin (CDDP), PC-9/CDDP and PC-14/CDDP, and to adriamycin (ADM), K-562/ADM, were used as target cells. PC-9/CDDP demonstrated a marked increase in susceptibility to killing by both peripheral blood lymphocytes (PBL) and LAK cells, as compared to the parental cell line, PC-9. The cytotoxicity of PBL and LAK cells against PC-14/CDDP and K-562/ADM was similar to that against their parental cell lines. Moreover, the combination of LAK and CDDP had a synergistic effect on PC-14 and PC-14/CDDP.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2498260      PMCID： PMC5917724          DOI： 10.1111/j.1349-7006.1989.tb02303.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


interleukin‐2‐activated killer cells cisplatin (cis‐diamminedichloroplatinum) adriamycin peripheral blood lymphocytes natural killer cells RPMI‐1640 medium with fetal bovine serum Eagle's minimum essential medium effector‐to‐target ratio
  16 in total

1.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones.

Authors:  T Tsuruo; H Iida-Saito; H Kawabata; T Oh-hara; H Hamada; T Utakoji
Journal:  Jpn J Cancer Res       Date:  1986-07

2.  Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.

Authors:  S Yanovich; R E Hall; C Weinert
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

3.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with adriamycin.

Authors:  J Y Leroux; G Mercier; D Oth
Journal:  Int J Immunopharmacol       Date:  1986

5.  Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL-2) against lung cancer cell lines by human tumor clonogenic assay (HTCA).

Authors:  J Fujita; N Saijo; Y Sasaki; H Futami; J Ishihara; H Takahashi; A Hoshi; A W Hamburger
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

6.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

7.  Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide.

Authors:  C Gambacorti-Passerini; M Radrizzani; E Erba; G Fossati; G Parmiani
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

8.  Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes.

Authors:  P Allavena; M Grandi; M D'Incalci; O Geri; F C Giuliani; A Mantovani
Journal:  Int J Cancer       Date:  1987-07-15       Impact factor: 7.396

9.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701
View more
  2 in total

1.  P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.

Authors:  B Savas; S P Cole; T Tsuruo; H F Pross
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

2.  Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.

Authors:  W Van de Vrie; S A Van der Heyden; E E Gheuens; A M Bijma; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.